Literature DB >> 24287173

The compromised inflammatory response to bacterial components after pediatric cardiac surgery is associated with cardiopulmonary bypass-suppressed Toll-like receptor signal transduction pathways.

Yi-ping Li1, Jie Huang2, Shun-gen Huang3, Yong-gen Xu3, Yun-yun Xu1, Jian-yi Liao3, Xing Feng1, Xue-guang Zhang4, Jiang Huai Wang5, Jian Wang6.   

Abstract

PURPOSE: Cardiopulmonary bypass (CPB) during pediatric cardiac surgery often elicits a systemic inflammatory response followed by a compromised immune response, which has been attributed to the morbidity of postoperative infection; however, the underlying mechanism(s) has not yet been fully elucidated. We hypothesized that CPB inhibits the activation of Toll-like receptor (TLR) signal transduction pathways, thereby causing an immunosuppressive state after pediatric cardiac surgery.
METHODS: We examined 20 children with congenital heart disease undergoing pediatric cardiac surgery.
RESULTS: Cardiopulmonary bypass differentially affected lipopolysaccharide (LPS)- or bacterial lipoprotein (BLP)-stimulated ex vivo production of proinflammatory and anti-inflammatory cytokines, with significantly diminished tumor necrosis factor α, interleukin (IL) 1β, IL-6, and IL-8, but substantially enhanced IL-10 production. Consistent with the reduced inflammatory response, CPB strongly inhibited LPS- or BLP-activated TLR signal transduction pathways in monocytes with down-regulated expression of CD14, TLR4, and TLR2 and with suppressed phosphorylation of nuclear factor κB p65, p38, and extracellular signal-regulated kinase 1/2.
CONCLUSIONS: These results indicate that CPB during pediatric cardiac surgery causes substantially reduced production of inflammatory cytokines in response to bacterial component LPS or BLP stimulation, which is associated with CPB-induced suppression of TLR-mediated signal transduction pathways. This reduced inflammatory response after CPB in children with congenital heart disease may predispose them to an increased risk of postoperative infection.
© 2014.

Entities:  

Keywords:  Cardiopulmonary bypass; Congenital heart disease; Inflammatory responses; Intracellular signal pathways; TLR signaling

Mesh:

Substances:

Year:  2013        PMID: 24287173     DOI: 10.1016/j.jcrc.2013.10.008

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  6 in total

1.  Injuries of myocardial cells and changes of myocardial enzymes after firearm wound-induced intestinal perforation in porcine abdomen.

Authors:  Hui-Chao Xue; Ze-Xin Li; Wei-Wei Zheng; Yun-Zhen Guo; De-Yuan Feng; Jiang-Wei Liu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 2.  Accelerated Cardiac Aging in Patients With Congenital Heart Disease.

Authors:  Dominga Iacobazzi; Valeria Vincenza Alvino; Massimo Caputo; Paolo Madeddu
Journal:  Front Cardiovasc Med       Date:  2022-05-26

3.  Serum TNF-α levels in children with congenital heart disease undergoing cardiopulmonary bypass: A cohort study in China and a meta-analysis of the published literature.

Authors:  Shu-Tian Song; Chuan-Ming Bai; Ji-Wu Zhou
Journal:  J Clin Lab Anal       Date:  2016-12-13       Impact factor: 2.352

4.  Skin-to-Skin Care is Associated with Reduced Stress, Anxiety, and Salivary Cortisol and Improved Attachment for Mothers of Infants With Critical Congenital Heart Disease.

Authors:  Amy J Lisanti; Abigail C Demianczyk; Andrew Costarino; Maria G Vogiatzi; Rebecca Hoffman; Ryan Quinn; Jesse L Chittams; Barbara Medoff-Cooper
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2020-11-09

5.  α7 nicotinic acetylcholine receptor agonist attenuates the cerebral injury in a rat model of cardiopulmonary bypass by activating the Akt/GSK3β pathway.

Authors:  Yingjie Sun; Dandan Song; Mei Wang; Keyan Chen; Tiezheng Zhang
Journal:  Mol Med Rep       Date:  2017-09-25       Impact factor: 2.952

6.  Cardiopulmonary Bypass Down-Regulates NOD Signaling and Inflammatory Response in Children with Congenital Heart Disease.

Authors:  Qinghua Yang; Jianyi Liao; Jie Huang; Yi Ping Li; Shungen Huang; Huiting Zhou; Yi Xie; Jian Pan; Yanhong Li; Jiang Huai Wang; Jian Wang
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.